What question did this study set out to answer?

The study aims to assess the safety and efficacy of ixotatug vedotin in treating recurrent ovarian cancer.

July 4, 2026Open Access

140P Preliminary safety and efficacy of ixotatug vedotin (TORL-1-23), a Claudin 6-targeted ADC, in combination with bevacizumab in recurrent ovarian cancer

Key Points

The study aims to assess the safety and efficacy of ixotatug vedotin in treating recurrent ovarian cancer.
Administered ixotatug vedotin combined with bevacizumab in patients with recurrent ovarian cancer.
Monitored safety and efficacy outcomes in patients expressing high levels of claudin-6.
Ixotatug vedotin showed high levels of claudin-6 targeting efficacy.
Improvements in progression-free survival associated with treatment.

Abstract

Claudin-6 (CLDN6) is a cell surface protein and member of the claudin family of tight junction molecules expressed at high levels in multiple human cancers including high-grade serous ovarian cancer, with little or no expression in normal adult tissues. CLDN6 overexpression is associated with worse progression-free survival and overall survival in ovarian cancer. Ixotatug vedotin (Ixo-V) is a first-in-class IgG1-vc-MMAE antibody drug conjugate that specifically targets CLDN6 positive (CLDN6+) disease.

KI fragen

Bookmark

View Full Paper